INTRODUCTION
Genomic instability is a major contributing factor to the development and onset of age-related diseases such as cancer (Maslov and Vijg, 2009; Negrini et al., 2010) . Cancer cells are often characterized by copy number alterations: gains or losses of chromosome arms and/or whole chromosomes as well as amplifications of smaller genomic fragments (Beroukhim et al., 2010; Hook et al., 2007; Stratton et al., 2009) . Genome-wide analysis of copy number changes in cancer has identified chromosomal regions with higher frequencies of amplification, which often contain putative oncogenes (Beroukhim et al., 2010) . In some cases, the oncogenes have been shown to impact cellular behavior (e.g., MYC and MCL1), whereas other genes within these regions do not have clear connections with tumorigenesis. The lack of obvious connection does not preclude the gene's involvement. For example, cellular stresses can select for gene amplification that will promote cancer cell survival, as exemplified by the amplification of dihydrofolate reductase when cells are treated with methotrexate (Schimke, 1984) . Even though cancer genomes frequently have altered chromosomal regions, there is little knowledge about the regulatory mechanisms or factors that are involved in promoting copy number alterations at specific regions of the genome.
Several mechanisms have been proposed for generating copy number variation (CNV). For example, many models for DNA amplification incorporate stalled replication forks and DNA double-strand breaks that are generated during replication. It has been proposed that these stalled/collapsed replication forks are associated with and can cause tandem duplications. A second mechanism proposed to contribute to CNV involves the use of breaks or repair intermediates as primers for rereplication of specific stretches of DNA, which can reincorporate into the genome, resulting in gene duplications or deletions. Alternatively, it is also possible that these events will not integrate in the genome (Hastings et al., 2009) . A third mechanism that could generate rereplicated fragments and copy number alteration is the head-to-tail collision of elongating DNA polymerases (Davidson et al., 2006; Hook et al., 2007) . Because chromatin structure impacts replication initiation and elongation efficiency as well as DNA damage response and repair (Alabert and Groth, 2012; Papamichos-Chronakis and Peterson, 2013) , the chromatin state or modifying enzyme(s) could have a significant impact on each of these possible mechanisms.
Recently, Kiang and colleagues demonstrated that local DNA fragment amplification occurs during S phase (Kiang et al., 2010) and that the chromatin context or chromosome microenvironments play a major role in this process. Consistent with an important role for the chromatin context, misregulation of the histone 4 lysine 20 monomethyltransferase KMT5A (H4K20me1, PR-Set7/ Set8) promotes rereplication, at least in part, by increasing H4K20me2/3 levels and promoting ORC recruitment through binding of H4K20me2 (Beck et al., 2012; Kuo et al., 2012; Tardat et al., 2010) . However, the role of methylation in modulating replication is not limited to the direct recruitment of DNA replication factors. For example, we have previously demonstrated that the H3K9me3 demethylase KDM4A/JMJD2A was able to increase accessibility and alter the replication timing at specific heterochromatic regions (Black et al., 2010) . The regulation of KDM4A protein levels is also important in modulating its chromatin occupancy, replication initiation, and S-phase progression (Van Rechem et al., 2011) . Furthermore, Mallette and colleagues demonstrate that increased KDM4A expression abrogates 53BP1 recruitment to DNA damage sites, suggesting a role for KDM4A in DNA damage response . Therefore, we hypothesize that overexpression of catalytically active KDM4A may provide a potential enzymatic link to the proposed methods for generating copy number alterations through replication abnormalities, which may contribute to copy number changes in cancer.
In this study, we analyzed The Cancer Genome Atlas (TCGA) data and observed that KDM4A is amplified and overexpressed in several tumor types. KDM4A overexpression in transgenic cells was sufficient to promote copy gain of specific chromosomal domains (e.g., 1q12). KDM4A-dependent copy gain was induced in less than 24 hr and required S phase. These copy gains were not stably inherited but were generated transiently in each subsequent S phase and cleared by late G2. KDM4A was the only KDM4 family member that generated the gains in a catalytically dependent manner. These copy gains were antagonized by coexpression of Suv39h1/KMT1A or HP1g, and H3K9 or H3K36 methylation interference promoted gain. Furthermore, KDM4A associated with replication machinery and promoted rereplication of regions exhibiting copy gain. KDM4A overexpression increased KDM4A, MCM, and DNA polymerase association as well as decreased HP1g occupancy at regions that undergo KDM4A-dependent rereplication. Interestingly, focal amplifications of 1q21 and Xq13.1 were correlated with KDM4A amplification in tumors, which was recapitulated in KDM4A-overexpressing cell lines. Our findings demonstrate that KDM4A overexpression results in site-specific copy gain of regions amplified in human tumors.
RESULTS

KDM4A Is Amplified and Overexpressed in Cancer
KDM4A has previously been demonstrated to be overexpressed in breast and lung cancer . However, a comprehensive profile of primary tumors for alterations in KDM4A expression levels has yet to be established. There are few insights into the mechanisms that promote increased expression in tumors. Therefore, we conducted a comprehensive analysis of KDM4A copy number and expression level in 1,770 primary tumor samples from eight different cancer types ( Figure S1 available online) represented in TCGA (Beroukhim et al., 2010) . We found evidence of increased KDM4A copy number (GISTIC annotation of +1 or +2; Mermel et al., 2011) in 18.9% of tumors (335 out of 1,770 samples; Figure 1A ) and copy loss in 22.1% of tumors (392 out of 1,770 samples; Figure 1A ). Furthermore, amplification or deletion of KDM4A resulted in increased or decreased KDM4A expression, respectively (Figures 1B and Figure S1A ). KDM4A was both amplified and deleted across many disparate cancer types, and KDM4A expression correlated with copy number in these samples (Figures S1E-S1L). We also observed amplification and deletion of KDM4B-D in cancer, which correlated with expression ( Figures S1B-S1D ). These data provide a molecular basis for the elevated KDM4A levels observed in different tumor samples.
Ovarian cancer was significantly enriched for KDM4A amplification, which was amplified in 46% of the tumors (94 out of 204, p = 1.4 3 10 À21 for gain versus no change and loss by Fisher's exact test), with relatively few examples of deletion (9.8%; 20 out of 204, samples) ( Figures 1C and S1I ). The amplification of KDM4A in ovarian cancer also correlated with increased expression ( Figures 1D and S1I ). In addition, KDM4A focal amplification (GISTIC +2) was significantly associated with the time to death in the ovarian cancer patient data set, with a median time to death of 691 days compared to 1,052 days without KDM4A amplification ( Figure 1E , p = 0.02); however, KDM4A loss (GISTIC À2 or À1) was not significantly different from patients without changes in KDM4A copy number (p = 0.85). In sharp contrast to KDM4A, few cases of focal amplifications were observed for KDM4B-D, and no statistical significance was associated with their focal amplifications and time to death ( Figures 1F-1H ). However, focal deletion of KDM4C (GISTIC À2) and broad loss or gain (GISTIC À1 or +1) of KDM4D modestly associated with poor outcome (p = 0.014, p = 0.013, and p = 0.018, respectively). These data highlight the differences between the KDM4 family and cancer outcome, which suggests nonoverlapping functions in certain cancer types. These data also suggest that KDM4A levels could function as a biomarker in ovarian cancer.
KDM4A Overexpression Promotes Copy Gain of 1q12
We previously demonstrated that KDM4A overexpression promoted faster S-phase progression, increased chromatin accessibility, and altered replication timing (Black et al., 2010) . KDM4A was also shown to impact the DNA damage response . For these reasons, we hypothesized that KDM4A overexpression may promote genomic instability, which is a hallmark of cancer (Luo et al., 2009; Hanahan and Weinberg, 2011) . Therefore, we stably overexpressed KDM4A in the karyotypically stable and immortalized, but not transformed, RPE1-hTERT (RPE) cell line (GFP, referred to as control or CTRL; GFP-KDM4A, referred to as KDM4A) (Jiang et al., 1999) . Similar to our previously reported 293T stable cells ( Figure S2A ), RPE stable cell lines expressed KDM4A about 2-to 3-fold over endogenous level ( Figure S2B ). Upon spectral karyotyping these cell lines, we did not observe major genomic events that were specific to the KDM4A cell lines when compared to CTRL cell lines (SKY; Figures 2A and 2B and Table S1 ). Similarly, G-band analysis of a 293T KDM4A-overexpressing stable cell line did not document any amplification, deletion, or translocation specific to GFP-KDM4A cells (data not shown). These data support the notion that modest KDM4A overexpression does not promote large-scale genomic instability. We reasoned that KDM4A might promote instability at specific genomic loci that could be below the detection threshold of SKY. In order to identify these candidate regions, we reanalyzed our chromatin immunoprecipitation (ChIP) on chip analysis of KDM4A binding in 293T cells ( Figure S2C ) (Van Rechem et al., 2011) for KDM4A enrichment by cytogenetic band. Of the top ten enriched cytogenetic bands, only 1q12 was specifically enriched in KDM4A-overexpressing cells when compared to control cells ( Figure S2C ). 1q12/21 is a region with frequent CNV in lung cancer, multiple myeloma, and congenital heart abnormalities and has been described as a susceptibility locus for schizophrenia and autism (Brunet et al., 2009; Brzustowicz et al., 2000; Inoue et al., 2004; Yakut et al., 2006) . To determine whether the copy number of 1q12 was altered following manipulation of KDM4A protein levels, we performed fluorescent in situ hybridization (FISH) in CTRL and KDM4A-overexpressing 293T cells ( Figures 2C-2K and S2D ). KDM4A overexpression resulted in increased copy number of 1q12h in 14% of cells ( Figure 2K ), which was not due to a gain of the entire 1q chromosome arm, as the 1q telomere did not have an increase in copy number (Figure 2K; 1qTel) . Furthermore, no other gains occurred at additional pericentric regions ( Figure 2K ). We further validated these results in the RPE stable cell lines used in the SKY analysis (Figures 2A, 2B, S2B) . Similar to the 293T cells, 17% of KDM4A-overexpressing RPE cells showed an increase in copy of 1q12h, whereas no significant changes in copy number were observed for the 1q telomere or other centromeres on chromosomes 2, 6, 8, or X (Figures 2L-2T ; Chr 2, 6, 8, X).
To eliminate the possibility that KDM4A promoted chromatin accessibility so that there was increased 1q12h detection, condensin 1 (CapD2) or condensin 2 (CapD3) were depleted from cells ( Figure S2F ). Depletion of either condensin did not increase detection of 1q12h amplification in CTRL or KDM4A cells (Figure S2G) . Therefore, the increased copy number of 1q12h in KDM4A cells is most likely not an artifact of increased chromatin accessibility. Furthermore, 1q12h copy gain was not due to alterations in p53 activity, as doxorubicin treatment resulted in p53 stabilization and target gene activation in CTRL and KDM4A cells ( Figures S2H and S2I ).
KDM4A-Dependent 1q12h Copy Gain Is Dose Dependent and Requires Catalytic Activity and Tudor Domains In order to determine whether the expression level and catalytic activity of KDM4A are required for 1q12h copy gain, we overexpressed catalytically active and inactive KDM4A (H188A; Whetstine et al., 2006) with and without KDM4A depletion by shRNA ( Figures 3A and S3A ). Transient overexpression of KDM4A was sufficient to promote 1q12h copy gain but not alter copy number of Chr 8. However, concomitant depletion of KDM4A suppressed 1q12h gain, which demonstrates the importance of increasing KDM4A levels in order to observe 1q12h gain ( Figures  3A and S3A) . Importantly, neither catalytically dead KDM4A overexpression (Figures 3A and 3B; H188A) nor KDM4A depletion promoted 1q12h copy gain, which emphasizes that the gain is not a dominant-negative effect due to KDM4A overexpression. We further demonstrated that 1q12h gain occurred in less than 24 hr of KDM4A transient overexpression in RPE cells ( Figures  3C, 3D , S3B, and S3C) while not altering copy gain at other regions ( Figure 3D ). Interestingly, KDM4B, KDM4C, or KDM4D overexpression for 24 hr did not alter 1q12h copy number (Figures 3E and S3C) . The copy gain required KDM4A catalytic activity (H188A) and enzymatic domains (JmjC and JmjN; referred to as DNC) in RPE cells ( Figures 3B, 3C , and S3B). However, the KDM4A catalytic domain alone was insufficient to generate 1q12h gain (Figures 3B and 3C; referred to as NC). Interestingly, the loss of the Tudor domains alone was sufficient to block the 1q12h gain (Figures 3B and 3C ; referred to as NCMP). Taken Arrowheads indicate foci in FISH images. Error bars represent the SEM. Asterisk indicates significant difference from GFP-CTRL (p < 0.05) by two-tailed Student's t test. Scale bars, 2 mm. See also Figure S2 and Table S1. together, these data emphasize that transient exposure to increased KDM4A levels is sufficient to promote 1q12h copy gain, but this can only occur with a catalytically active enzyme and functional Tudor domains.
Interfering with H3K9 or H3K36 Methylation Promotes 1q12 Copy Gain
The requirement for KDM4A catalytic activity to promote 1q12 copy gain suggests that demethylation of chromatin or a nonhistone target is important for proper regulation of 1q12h ploidy. Recently, Lewis and colleagues demonstrated that H3.3 variants with a methionine in place of the lysine (i.e., H3K27M, H3K9M, and H3K36M) can inhibit EZH2 (K27M), G9a (K9M), and Suv39h1 (K9M), as well as reduce H3K36me3 levels (K36M) (Lewis et al., 2013) . Therefore, these H3.3 variants were used to ascertain whether interfering with methylation at any one of these lysines could promote 1q12h copy gain. Each variant was expressed and successfully incorporated into chromatin in 24 hr and reduced the corresponding trimethylation ( Figures  S3D and S3E) . Expression of H3.3 WT, G34V, and H3K27M failed to promote 1q12h copy gain; however, expression of either H3.3K9M or H3.3K36M was sufficient to promote 1q12h gain ( Figure 3F ; p = 0.026 for K9M and p = 0.006 for K36M). Further- more, the 1q12h gain was not caused by a gain of chromosome 1, as there was not an increase in 1q Tel or in the 1q23.3 cytogenetic band midway down the 1q arm ( Figure 3F ). Because H3.3K9M promoted copy gain at 1q12h and inhibits Suv39h1 (Lewis et al., 2013) , we reasoned that overexpression of the H3K9me3 methyltransferase Suv39h1 may suppress KDM4A-dependent copy gain. Consistent with this prediction, coexpression of Halo-Suv39h1 was sufficient to abrogate KDM4A-dependent 1q12h copy gain (p = 0.0003 for KDM4A vs NHF; p = 0.0055 for KDM4A + Suv39h1 vs KDM4A; and p = 0.47 for KDM4A+ Suv39h1 vs NHF) ( Figures 3G and S3F ). These results highlight the importance of methylation in modulating site-specific copy gain, especially the lysines that are substrates for KDM4A.
HP1g Antagonizes KDM4A-Dependent Increased 1q12 Copy Number KDM4A-dependent changes in cell-cycle progression and replication timing at Chr1 sat2 are antagonized by HP1g overexpression (Black et al., 2010) . Therefore, we hypothesized that HP1g overexpression could antagonize the increased copy number of 1q12 in KDM4A-overexpressing cells. Cotransfection of HP1g reduced the 1q12h copy gain to levels comparable to that seen in control cells (p = 0.29 for KDM4A + HP1g vs GFP-CTRL+ HP1g; and p = 0.009 for KDM4A + HP1g vs KDM4A + RFP-CTRL) ( Figures 3H and S3G) . Surprisingly, transfection of HP1g into RPE cells stably overexpressing KDM4A or stably co-overexpressing HP1g and KDM4A did not reverse the increased copy number of 1q12h (data not shown). These results imply that, once an altered chromatin conformation is established, HP1g is insufficient to restore proper regulation of 1q12 copy number in KDM4A overexpressing cells.
1q12 Copy Gain Is Not Stably Inherited and Requires S Phase Because KDM4A overexpression promotes 1q12 gain, we asked whether the increased copy number was stably inherited or was regenerated during subsequent cell cycles. First, single-cell clones were established from our stably overexpressing KDM4A RPE cell line and were assayed by 1q12h FISH (Figure 4A) . If the copy number of 1q12h was stably inherited, some clones should have 100% of cells with 1q12h copy gain. Instead, we observed a distribution of copy gain between 1.5% and 37%, which supports the model that 1q12 gain is most likely not stably inherited ( Figures 4A and S4A ). The clones lacking increased copy of 1q12h (below black dashed line) no longer overexpressed KDM4A ( Figure S4A ). Furthermore, the average of all clones assayed was 17.0%, agreeing with our analysis of the starting stable population ( Figures 4B and 2T, respectively) .
We next investigated whether stably overexpressing KDM4A RPE cells gain extra copies of 1q12h during each cell division. The 1q12h copy gain was eliminated in KDM4A overexpressing RPE cells arrested in G1/S with HU ( Figures 4C and S4B ). Because apoptosis was not increased in asynchronous or HUarrested KDM4A cells, the lack of copy gain was not due to increased apoptosis removing cells with extra 1q12h (Figure S4C ). However, doxorubicin treatment could induce apoptosis in both CTRL and KDM4A cells, which was significantly reduced in KDM4A-overexpressing cells ( Figure  S4C ). We then tested whether 1q12h gain persisted through G2 by arresting cells in late G2 with the CDK1 inhibitor R03306 ( Figure S4B ; Vassilev, 2006) . KDM4A cells arrested in late G2 and did not display 1q12h copy gain ( Figure 4D ).
Given that KDM4A-dependent 1q12h copy gain did not occur during G1/S or G2 arrest, we hypothesized that KDM4A promotes copy gain during S phase. In agreement with this hypothesis, GFP-KDM4A cells, but not GFP-CTRL cells, were able to promote additional copies of 1q12h, but not Chr 8 centromere following HU release ( Figures 4E and 4F) . The additional copies occurred between 2 and 6 hr post-HU release and were lost between 8 and 10 hr following release. Taken together, our data support a model whereby KDM4A promotes copy gain of specific chromosomal regions during S phase, which are then eliminated by the end of the G2 phase of cell cycle.
KDM4A Associates with Replication Machinery and Promotes Rereplication of 1q12
In order to gain molecular insight into how KDM4A is involved in generating 1q12h copy gain, we identified KDM4A-interacting proteins by performing mass spectrometry analysis of proteins interacting with Halo-KDM4A. We observed a significant enrichment for proteins involved in replication using IPA ( Figure 5A ; p = 0.00000795). Interestingly, many of these proteins are required for rereplication (e.g., MCMs and DNA polymerases; Arias and Walter, 2007; Snaith and Forsburg, 1999) .
Previous work verified KDM4A associations with cullin 1 (Van Rechem et al., 2011) and p53 (Kim et al., 2012) . We further validated additional interactions by conducting endogenous KDM4A coimmunoprecipitation with MCM2, MCM3, and MCM7 or Halo-tagged DNA polymerase subunits ( Figures 5B and S5A) . Although MCM2 was not identified in our mass spectrometry analysis, it associated with KDM4A, suggesting that the entire MCM complex interacts with KDM4A.
Because KDM4A overexpression promoted copy gain in a replication-dependent manner and interacted with DNA polymerases and the replication licensing machinery, we hypothesized that KDM4A overexpression was promoting rereplication within 1q12. To test this hypothesis, we utilized cesium chloride density gradient centrifugation ( Figure S5B ). Our labeling procedure was performed for less than one complete cell cycle, producing an enrichment in heavy-light (H:L)-replicated DNA while still maintaining an unreplicated light-light fraction (L:L). We did not detect a peak of enrichment of H:H DNA, indicating that KDM4A overexpression does not promote widespread rereplication, as seen with other chromatin regulators (KMT5A; Tardat et al., 2010) . We pooled and purified the fractions in which the H:H DNA should separate and then assayed the rereplicated DNA for specific regions. Because Chr1 sat2 resides in 1q12 (Wong et al., 2001) and is bound and modulated by KDM4A, we reasoned that it could be a rereplicated target. We observed a 7-fold enrichment of Chr1 sat2 in the rereplicated fraction from KDM4A-overexpressing cells, whereas the b-actin locus and a region near the X centromere, which we previously reported as a KDM4A target (Black et al., 2010) , were not enriched (Figures 5C and S5C). The enrichment in Chr1 sat2 rereplication represented a small amount of the input DNA and was consistent with a subpopulation of cells generating and losing the 1q12h copy gain ( Figure S5C ). Taken together, our data demonstrate that KDM4A associates with replication proteins and promotes rereplication at a specific locus that exhibits copy gains.
KDM4A Overexpression Promotes Chromatin State Changes and Recruitment of Replication Machinery
Our data support a model whereby KDM4A overexpression promotes methylation changes, displacement of HP1g, and recruitment of replication machinery to specific genomic regions, resulting in rereplication. To test this model, we performed ChIP experiments to evaluate methylation levels, HP1g enrichment, and replication machinery occupancy at Chr1 sat2. As a negative control, we identified an intergenic region on chromosome 10 (Chr10) that is acetylated at H3K9 in numerous cell types (according to UCSC browser; data not shown) that should not be enriched for H3K9me3 or KDM4A. KDM4A overexpression increased KDM4A recruitment to Chr1 sat2, but not Chr10 ( Figure 5D ), which corresponded to a loss of H3K9me3 and HP1g depletion ( Figures 5E and 5F ). We did not observe any change in H3K36me3 at Chr1 sat2, which was consistent with our previous findings in 293T cells (Black et al., 2010) . Finally, both MCM7 and Pola were enriched at Chr1 sat2, but not at Chr10, upon KDM4A overexpression ( Figures 5G and 5H , respectively). Our data demonstrate that KDM4A overexpression promotes H3K9me3 and HP1g loss, increased replication machinery recruitment, and rereplication.
Identification of Regions Coamplified with KDM4A in Cancer
To identify additional regions that have copy gains upon KDM4A overexpression, we determined whether KDM4A focal amplification (1p34.2) in primary tumors was correlated with copy gains of any of the 807 cytogenetic bands in 4,420 tumor samples (Figure 6A , which represents 19 tumor types, including the 8 analyzed in Figure S1 ). We observed correlated copy gains from 1p11.2 through 1q21.3 on chromosome 1 in two independent statistical tests ( Figures 6A and S6A , blue shading; see Experimental Procedures). Due to the minimal sequence annotation and repetitive nature of 1q12, we did not calculate a correlation for this cytogenetic band. However, the cytogenetic bands immediately flanking 1q12 (1p11.2 and 1q21.1) exhibited cogain with KDM4A amplification, which suggests that 1q12 is likely coamplified in these tumors. These coamplified regions were specific to KDM4A because there was not a strong correlation when the identical analysis was performed with respect to KDM4B coamplification ( Figures 6B and S6B) . We observed that individual coamplified regions could universally be observed, whereas others could be differentially regulated in a tumor-and/or tissue-specific manner. For example, the ovarian cancer data sets demonstrated coamplification with 1p11.2-1q21.3, whereas some KDM4A-coamplified regions were lost (e.g., the region on 17q positions 17q24.2 to 17q25.3) and others were enhanced (e.g., the region on X chromosome positions Xp11.2 to Xq13.2) in the ovarian cancer profile ( Figures 6C and S6C ).
Next, we tested whether gains in 1q21.1-1q21.3 were affected by the amplification level of KDM4A ( Figures 6D-6F and S6D-S6F). Indeed, when KDM4A had a high-level focal amplification (GISTIC +2), a significantly greater fraction of samples were amplified in 1q21.1-1q21.3 compared to cases in which KDM4A was not amplified (GISTIC 0; Fisher's exact test; p = 2 3 10 À9 in 1q21.1, 1.9 3 10 À9 in 1q21.2, and 1.02 3 10 À10 in 1q21.3) ( Figures 6D-6F ). When comparing lower-level amplification of KDM4A (GISTIC +1) to the KDM4A-unamplified cases, we observed a reduced sample fraction but still highly significant amplification of 1q21.1-1q21.3 (p = 2.04 3 10 À25 in 1q21.1, 6.28 3 10 À22 in 1q21.2, and 3 3 10 À24 in 1q21.3). In contrast, when stratifying the samples based on KDM4B amplification status ( Figures 6G-6I and S6G-S6I), the differences are not significant (all p values > 0.1 by Fisher's exact test), although a minimal trend in the same direction is observed. These results demonstrate that KDM4A amplification in tumors correlated with amplification of specific cytogenetic bands, which suggests that KDM4A may promote site-specific copy gains in vivo.
Copy Gain and Rereplication Occur in Regions Coamplified in Tumors
Because 1q21.1-1q21.3 amplification correlated with KDM4A amplification, we assessed whether these regions were gained by FISH and rereplicated by density gradient centrifugation in transgenic cell lines. We observed increased copy number of 1q12 through 1q21.2 in our KDM4A-overexpressing cells, but not in control cells (Figures 7A and 7B ). Our coamplification analysis of all tumors indicated that the correlation with KDM4A copy number diminished at 1q23.3, suggesting that 1q23.3 is not amplified in KDM4A-overexpressing cells, which was in fact the case in KDM4A-overexpressing RPE cells ( Figures 7A and 7B) . We then evaluated copy gain of other chromosomal domains identified through our coamplification analysis. We chose to examine the small focal peak on the X chromosome (Xp11.2-Xq13.2), which was specific to coamplification with KDM4A across all cancers and was even more enriched in ovarian cancer ( Figures 6A and 6C, respectively) . KDM4A-overexpressing RPE cells exhibited Xq13.1 copy gains, but not the X centromere or Xq13.2 ( Figures 7C and 7D ). Xq13.1 as well as 1q12/21 and 1q21.2 copy gains were also observed in 293T cells overexpressing KDM4A ( Figure S6J ). These data demonstrate that KDM4A-coamplified regions in primary tumors are generated by KDM4A overexpression in transgenic cell lines.
The coamplification analysis of tumor data sets does not distinguish whether the entire intervening sequence between 1q12h and 1q21.3 was amplified in the same tumor cells. Therefore, we scored the 1q12/21 or 1q21.2 FISH probes with the 1q12h probe in the same KDM4A-overexpressing cells ( Figures  7A and 7E-7U ). We observed that approximately two-thirds of the KDM4A-overexpressing cells with 1q12h amplification also had 1q12/21.1 amplification, whereas approximately one-third had only 1q12/21.1 copy gain but lacked 1q12h gain ( Figure 7U ). In the case of 1q12h or 1q21.2 amplification, the majority of cells had gains in one or the other cytogenetic band (Figures 7M-7U ). Taken together, these data demonstrate that the entire region between 1q12h and 1q21.3 is not contiguously amplified but that KDM4A is directing copy gain within these cytogenetic bands. The ability to detect nonoverlapping foci also suggests that the additional copies may exist as extrachromosomal pieces. This possibility was further supported by the fact that 1q12/21 FISH marked the additional 1q12/21 copy adjacent to or physically distinct from the chromosome 1 painted territory ( Figures S7A-S7L) .
To address whether these gained regions were through rereplication, we assayed our CsCl gradient H:H fraction for regions under our FISH probes in the indicated cytogenetic bands (Figure 7V) . We observed rereplication at 1q12h (indicated by Chr1 sat2), 1q12/21.1, 1q21.2, and 1q21.3, but not in 1q23.3 or on Chr10. Rereplication was detected inside Xq13.1, but not near the X centromere. In addition, the rereplicated regions were bound by KDM4A, which was further enriched upon KDM4A overexpression ( Figures 7W and S6K) . As with Chr1 sat2, KDM4A overexpression promoted loss of HP1g ( Figure 7X ) and recruitment of MCM7 and Pola to 1q21.2 and Xq13.1 ( Figures  7Y and 7Z, respectively) . Taken together, our data are consistent with the model that KDM4A overexpression promotes copy gain and rereplication at specific sites within the genome in vivo (tumors) and in vitro (transgenic cell lines).
DISCUSSION
Genomic instability is a major contributing factor to the development and onset of age-related diseases. Cancer cells often contain alterations in copy number of genes, specific genomic regions, chromosome arms, and entire chromosomes. However, the underlying molecular mechanisms that lead to these copy number alterations are poorly understood. Here, we report that overexpression of a single chromatin modifying enzyme, KDM4A, is sufficient to promote rereplication and copy gain of specific chromosomal domains. Furthermore, KDM4A-dependent amplified regions are found coamplified with KDM4A in primary tumors. Our results support a model in which increased expression of KDM4A promotes recruitment of KDM4A to specific genomic regions and promotes rereplication ( Figure S7M ).
KDM4 Members and Cancer
Our results demonstrate that KDM4A is amplified in different tumor types and correlates with increased KDM4A expression. Intriguingly, when compared to other tumor types, ovarian cancer is enriched for amplifications of KDM4A, which correlate with poor outcome in these cases. Levels of KDM4A may therefore represent a good biomarker for ovarian cancer, especially with respect to novel therapies that target this lysine demethylase. In addition, ovarian patients with increased levels of KDM4A may respond more poorly to S-phase chemotherapeutics, as KDM4A overexpression resulted in better recovery from HU (Black et al., 2010) . Consistent with this possibility, ovarian cell lines with 1q12-21 amplification are often more resistant to cisplatin treatment (Kudoh et al., 1999; Takano et al., 2001) . Interestingly, drug resistance in multiple myeloma is also associated with 1q12-21 amplification (Inoue et al., 2004) . Addressing the relationship between KDM4A, 1q12-21 coamplification, and drug responses will be important in future studies. Even though KDM4 family members have a high degree of homology, they have different distribution of genomic anomalies in cancer. We observed focal deletions in KDM4B-D, whereas none were observed in KDM4A across the eight different tumor types (Figures S1A-S1D ). We also found that KDM4A was the only family member that had a correlation between focal amplification and poor outcome for ovarian cancer patients. Thus, it is intriguing to speculate that KDM4 family enzymes may play different roles in ovarian cancer and other tumor types. Overall, our data highlight the idea that these family members are not created equal but, most likely, have their own specific roles in cancer and in other diseases.
Chromatin Environment and KDM4A-Dependent Copy Gain Work in yeast demonstrates that specific genomic regions can generate extra DNA fragments in S phase, which depends on the chromatin environment (Kiang et al., 2010) . These observations are consistent with our KDM4A-dependent rereplication of specific chromosomal regions. These regions are enriched for KDM4A binding upon overexpression of KDM4A, rereplicate, and have increased copy number during S phase. Interestingly, not all KDM4A-occupied sites are rereplicating in the cell lines tested ( Figure 7V ). However, this could reflect the chromatin environment in these particular cells or distinct chromatin states influenced by other chromatin modifiers. This would be consistent with our ability to see Xq13.1 and X centromere copy gain in KDM4A focally amplified tumors while only seeing the copy gain and rereplication of Xq13.1 in our transgenic cell lines. Thus, different genomic regions may be susceptible to KDM4A-dependent rereplication in specific tissue types. Consistent with the model that chromatin state impacts copy gain, we demonstrated that interfering with H3K9 or K36 methylation resulted in the site-specific gain of 1q12h in 24 hr, whereas overexpression of Suv39h1 or HP1g was able to suppress the 1q12h gain. Surprisingly, we were unable to reverse KDM4A-dependent copy gains in cells stably overexpressing KDM4A by overexpressing HP1g even though these copy gains are regenerated each cell cycle. This observation supports a model whereby KDM4A may establish a chromatin state that promotes rereplication and increased copy number of specific chromosomal regions. Formation of this chromatin state could be antagonized by HP1g, but not reversed once established. Taken together, these data strongly suggest that the reader, the lysine, and the KDM/KMT balance are required to maintain regulation at these regions. Therefore, we hypothesize that the local chromatin environment will be an important determinant in designating whether certain regions are more susceptible to copy gains and rereplication (see Figure S7M ). Based on our observations, we also believe that other methyltransferases or chromatin modulators (e.g., readers or remodelers) may be able to block or reset the established chromatin state in KDM4A-overexpressing cells or that these modulators may have their own independent roles in regulating site-specific copy gains.
KDM4A and Rereplication
Increased KDM4A occupancy promotes a more open chromatin environment through decreasing H3K9me3 and HP1g occupancy ( Figure S7M ; Black et al., 2010) . KDM4A overexpression also promotes recruitment of the replication licensing machinery and DNA polymerases to sites of rereplication and copy gain (Figure S7M, model) . Because copy gains require the KDM4A Tudor domains, we favor the model that KDM4A directly increased chromatin accessibility and, in turn, loading of the MCM and replication complex on chromatin ( Figure S7M ). This loading and rereplication could occur in the absence of CDT1, CDC6, and ORC, as they are not necessary for replication after MCMs have been successfully loaded (Arias and Walter, 2007) . However, the more open chromatin could independently promote inappropriate recruitment of MCMs and DNA polymerases to unused or reused origins, thus promoting rereplication (Figure S7M ). This later model would be consistent with the observation that interfering with H3K9 or K36 methylation can promote the site-specific gain in cells with wild-type KDM4A levels. Regardless of the exact details, the data presented in this study support the model that alterations of heterochromatin and methylation at specific regions are more prone to rereplication and, in turn, copy gain.
KDM4A and Extrachromosomal DNA
Because the extra copies of 1q12 are not inherited but are removed prior to completion of G2, it is likely that such regions exist as extrachromosomal DNA (Figures S7H and S7L ). As such, it is possible that KDM4A is promoting rereplication at regions that promote head-to-tail collision of one replication fork chasing another ( Figure S7M ). This model fits a previous study showing that deregulation of replication licensing promotes DNA fragmentation and was consistent with fork collision (Davidson et al., 2006) . The presence of these fragments could also explain why KDM4A-overexpressing cells exhibit a moderate increase in p53 stabilization ( Figure S2H) ; that remains below the threshold required to elicit the p53 checkpoint (Kracikova et al., 2013) . It is also possible that site-specific rereplication may not be restricted to cancer cells. Transiently upregulating enzymes that direct site-specific rereplication to increase copy number of specific genes may be a general mechanism to allow cells the plasticity to respond to developmental, environmental, or stress conditions without altering their genetic makeup.
KDM4A-Dependent Transient Copy Gain
Because transient KDM4A overexpression was sufficient to promote localized changes in copy number in a single cell cycle, the amplification of specific regions may precede genetic changes in tumors. For instance, transient misregulation of chromatin regulators by altered environmental factors, metabolic changes, hypoxia, or miRNAs could lead to temporary changes in copy number of small genomic regions. If these regions contain oncogenes, this could create a feedback loop that promotes tumorigenesis while masking the originating event (e.g., transient upregulation of KDM4A). Of note, several putative oncogenes reside in the 1q12 and 1q21 cytogenetic bands, including BCL9 and MCL1. In fact, KDM4A binds the BCL9 locus and causes both copy gain and rereplication of this site (1q21.2 region, Figures 7W and 7V, respectively) . However, we do not observe increased expression of Bcl9, which likely reflects the lack of additional stimulus, transcription factors, or the low percentage of cells with this particular copy gain (data not shown).
It remains unclear how the rereplicated regions are removed as cells exit S phase and enter G2/M. It is possible that cells possess an active method for degradation or removal of these regions. Understanding the events leading to removal of inappropriately amplified regions could be critical to helping to identify pathways that may be misregulated in cancer and lead to the accumulation and inheritance of copy number changes. We hypothesize that other events could then promote incorporation of these transiently amplified regions and, in turn, influence tumorigenesis.
Conclusions
It is clear that the chromatin context influences replication timing and initiation choices. However, chromatin may additionally play an important role in ensuring replication fidelity and preventing rereplication. Distinct chromatin domains may have increased propensity for rereplication under different circumstances and cell types. This is supported by work in Drosophila that demonstrates that heterochromatic regions rereplicate upon loss of geminin (Ding and MacAlpine, 2010) . Additionally, some chromatin modifiers such as KMT5A/B/C regulate rereplication on a more global scale (Beck et al., 2012; Tardat et al., 2010) . Taken together, these results suggest that proper regulation of chromatin state is critical for suppressing rereplication. Therefore, a ''chromatin checkpoint'' may be intimately associated with the timing of replication and the propensity to undergo rereplication and copy gain.
Although we have uncovered a single enzyme that can regulate site-specific copy gain, several additional questions remain to be answered ( Figure S7M ). How does the chromatin environment regulate CNV? Is regulation of methylation of nonhistone substrates involved in modulating copy number (e.g., replication machinery and/or HP1)? Do additional chromatin modifiers regulate CNV and contribute to tumor heterogeneity? What events could promote transient copy gains to be inherited? Future studies that identify additional factors and/or stimuli that address these questions will allow for a more complete picture surrounding copy number variation, rereplication, genome stability, and cancer to emerge.
EXPERIMENTAL PROCEDURES
Extended Experimental Procedures are included in the Supplemental Information.
Cell Culture
Generation of stable cell lines, constructs, and antibodies used can be found in the Extended Experimental Procedures. Transient H3.3 variant RPE cells were transduced with lentiviral stocks provided from the Allis lab in the presence of 8 mg/ml polybrene for 8 hr (Lewis et al., 2013) . Subcellular Localization and Catalytic Activity of KDM4A Deletion Fragments H3K36me3 and subcellular localization were assayed by examining transfected cells (positive for HA staining; HA.11 Covance) following fixation in 3.7% PFA in PBS (Whetstine et al., 2006) .
Immunoprecipitation and Chromatin Immunoprecipitation
HaloTag-purified KDM4A complexes were analyzed and processed by MS Bioworks (Ann Arbor, Michigan), with details in the Extended Experimental Procedures. Immunoprecipitations (IP) were performed essentially as described in Van Rechem et al. (2011) .
Chromatin IPs were performed as in Black et al. (2010) with some minor changes. Sonication was performed using a Qsonica Q800R system with a constant chiller. RPE cells were arrested in 2 mM HU for 20 hr prior to crosslinking to assess enrichment in KDM4A, HP1g, H3K9me3, H3K36me3, and DNA polymerase a at G1/S transition. Data presented are averages from the two independently prepared polyclonal RPE cell lines from at least two independent chromatin preparations per cell line.
Fluorescent In Situ Hybridization
Fluorescent in situ hybridization (FISH) was performed as described in Manning et al. (2010) . Probes for 1q12h, 1q telomere, 6p21/chr 14 IGH translocation, and chromosomes 2, 6, 8, and X alpha satellite were purchased from Rainbow Scientific. Probes for 1q12/21.1 (RP11-17L12), Xq13.2 (RP11-451A22), and Xq13.1 (RP11-177A4) were purchased as BAC clones from Children's Hospital Oakland Research Institute (CHORI BacPac) FISH verified clone repository. Probes for 1q21.2 (BCL9) and 1q23.3 were purchased from Agilent (SureFISH). For RPE cells, copy gain was scored as any cell with three or more distinct foci. For 293T cells, copy gain was scored for any cell with five or more distinct foci. Comprehensive methods can be found in the Extended Experimental Procedures.
Cesium Chloride Gradient Centrifugation RPE cells were treated with 100 mM BrdU 14 hr prior to harvest. DNA was purified, digested with RNase A, EcoRI, and BamHI (NEB), and resuspended in TE. 100 mg of DNA was mixed with CsCl in TE (refractive index of 1.4015-1.4031). The CsCl gradient was centrifuged at 44,400 RPM in a VTi-65 rotor for 72 hr at 25 C. Fractions were collected in $200 ml aliquots, and DNA concentration was measured by Nanodrop. Appropriate fractions were pooled, dialyzed, concentrated, and ethanol precipitated. Each rereplicated pool was diluted to 15 ng/ul stock, and 7.5 ng of rereplicated DNA pool was analyzed by qPCR. Each sample was normalized to its own input prior to determination of fold change in rereplication. Primers used in this study will be provided upon request.
Determination of Cytoband Copy Number and Correlation with KDM4A Sample-specific mean focal copy numbers for 807 cytobands including X chromosome were annotated by taking an average of GISTIC annotated focal copy numbers for every gene within the same cytoband. The p values for the mean focal copy number changes between KDM4A copy-gained samples (GISTIC annotation = +1 or +2) and KDM4A copy-neutral samples (GISTIC annotation = 0) across 807 cytobands were annotated by two independent statistical tests ( Figures 6A-6C and S6A-S6C; see the Extended Experimental Procedures for details). As positive controls, we also calculated the significance using the gene-specific copy number for KDM4A and KDM4B. The empirical cumulative distribution functions (the fraction of samples below the given mean focal copy) were determined by enumerating samples having the mean focal copy number less than or equal to the value on the x axis in Figures S6D-S6I for KDM4A-and KDM4B-amplified (+2), copy-gained (+1), and copy-neutral samples (0). Procedures for RNA-seq and ovarian cancer outcome can be found in the Extended Experimental Procedures. 
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